Transcode Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Apr 15, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 15, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page)
POWER OF ATTORNEY AND SIGNATURES
Each individual whose signature appears below hereby constitutes and appoints Thomas A. Fitzgerald, MBA as such person’s true and lawful attorney-in-fact and agent with full power of substitution and re-substitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file or cause to be filed the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K and Power of Attorney has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| NAME | | TITLE | | DATE |
|---|---|---|---|---|
| | | | | |
| | | | | |
| /s/ Philippe P. Calais | | Director, Chairman and Chief Executive Officer (Principal Executive Officer) | | April 15, 2026 |
| Philippe P. Calais, PhD | | | | |
| | | | | |
| /s/ Thomas A. Fitzgerald | | Director and Chief Financial Officer (Principal Financial and Accounting Officer) | | April 15, 2026 |
| Thomas A. Fitzgerald, MBA | | | | |
| | | | | |
| /s/ Elizabeth Czerepak | | Director | | April 15, 2026 |
| Elizabeth Czerepak | | | | |
| | | | | |
| /s/ Erik Manting | | Director | | April 15, 2026 |
| Erik Manting, PhD | | | | |
| | | | | |
| /s/ Magda Marquet | | Director | | April 15, 2026 |
| Magda Marquet, PhD | | | | |
| | | | | |
| /s/ Jack Stover | | Director | | April 15, 2026 |
| Jack Stover | | | | |
Table of Contents
| | Page |
|---|---|
| Report of Independent Registered Public Accounting Firm | F-2 |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-3 |
| Consolidated Statements of Operations for the Years Ended December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Changes in Series A Non-Voting Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Years Ended December 31, 2025 and 2024 | F-5 |
| Statements of Consolidated Cash Flows for the Years Ended December 31, 2025 and 2024 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.